4//SEC Filing
NIFFENEGGER KATHI 4
Accession 0001654954-22-014746
CIK 0001540159other
Filed
Nov 3, 8:00 PM ET
Accepted
Nov 4, 3:27 PM ET
Size
9.8 KB
Accession
0001654954-22-014746
Insider Transaction Report
Form 4
NIFFENEGGER KATHI
Chief Financial Officer
Transactions
- Award
Common Shares
2022-11-02$1.13/sh+8,888$9,999→ 10,715 total(indirect: By Trust) - Award
Common Share Warrants (Right to Buy)
2022-11-02+4,444→ 4,444 total(indirect: By Trust)Exercise: $1.50→ Common Shares (4,444 underlying) - Award
Common Share Warrants (Right to Buy)
2022-11-02+4,444→ 4,444 total(indirect: By Trust)Exercise: $1.00→ Common Shares (4,444 underlying)
Footnotes (3)
- [F1]The reported securities are included within 8,888 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share.
- [F2]Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date.
- [F3]Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date.
Documents
Issuer
Edesa Biotech, Inc.
CIK 0001540159
Entity typeother
Related Parties
1- filerCIK 0001620146
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 8:00 PM ET
- Accepted
- Nov 4, 3:27 PM ET
- Size
- 9.8 KB